Literature DB >> 17059365

Immunotoxin treatment of cancer.

Ira Pastan1, Raffit Hassan, David J FitzGerald, Robert J Kreitman.   

Abstract

Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17059365     DOI: 10.1146/annurev.med.58.070605.115320

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  137 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

3.  Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.

Authors:  Neal Luther; Nai-Kong Cheung; Eleni P Souliopoulos; Ioannis Karampelas; Ioannis Karempelas; Daniel Bassiri; Mark A Edgar; Hong-Fen Guo; Ira Pastan; Philip H Gutin; Mark M Souweidane
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

4.  Internalization of biotinylated compounds into cancer cells is promoted by a molecular Trojan horse based upon core streptavidin and clostridial C2 toxin.

Authors:  Jörg Fahrer; Joschua Funk; Maren Lillich; Holger Barth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-07       Impact factor: 3.000

5.  Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Authors:  Rajat Singh; Yujian Zhang; Ira Pastan; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 6.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

7.  The 1.8 Å cholix toxin crystal structure in complex with NAD+ and evidence for a new kinetic model.

Authors:  Robert J Fieldhouse; René Jørgensen; Miguel R Lugo; A Rod Merrill
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 8.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 9.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

10.  Crystallization and preliminary X-ray diffraction data analysis of stenodactylin, a highly toxic type 2 ribosome-inactivating protein from Adenia stenodactyla.

Authors:  Giovanna Tosi; Simona Fermani; Giuseppe Falini; Letizia Polito; Massimo Bortolotti; Andrea Bolognesi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.